Article thumbnail

Bicyclic triterpenoid Iripallidal induces apoptosis and inhibits Akt/mTOR pathway in glioma cells

By Nitin Koul, Vivek Sharma, Deobrat Dixit, Sadashib Ghosh and Ellora Sen
Topics: Research Article
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2007). al: A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene
  2. (2008). Ali-Osman F: Constitutively Activated
  3. (2008). Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. Clin Cancer Res
  4. (2005). DE: Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3. Cancer research
  5. (2007). DM: Defining the role of mTOR in cancer. Cancer cell
  6. E: HDAC inhibitor Scriptaid induces glioma cell apoptosis through JNK activation and inhibits telomerase activity. Journal of cellular and molecular medicine
  7. (2007). E: Kaempferol induces apoptosis in glioblastoma cells through oxidative stress. Molecular cancer therapeutics
  8. (2009). E: Manumycin inhibits STAT3, telomerase activity and growth of glioma cells by elevating intracellular reactive oxygen species generation. Free radical biology & medicine
  9. (2008). Ebselen sensitizes glioblastoma cells to Tumor Necrosis Factor (TNFalpha)-induced apoptosis through two distinct pathways involving NF-kappaB downregulation and Fas-mediated formation of death inducing signaling complex. International journal of cancer
  10. (2000). Elledge SJ: The DNA damage response: putting checkpoints in perspective. Nature
  11. (2008). et al: Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS medicine
  12. (2003). et al: Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replicationdependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. The Journal of biological chemistry
  13. (2009). et al: S9, a novel anticancer agent, exerts its antiproliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeleton. PloS one
  14. (2003). F: Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events. The American journal of pathology
  15. (2000). Functional interaction of STAT3 transcription factor with the cell cycle inhibitor p21WAF1/CIP1/SDI1. The Journal of biological chemistry
  16. (2007). Heimberger AB: A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer research
  17. (1991). Hortobagyi GN: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.
  18. (2009). Ionizing radiation up-regulates telomerase activity in cancer cell lines by post-translational mechanism via ras/phosphatidylinositol 3-kinase/Akt pathway. Clin Cancer Res
  19. (2003). JC: Integration of DAG signaling systems mediated by PKC-dependent phosphorylation of RasGRP3. Blood
  20. (1998). JC: RasGRP, a Ras guanyl nucleotide- releasing protein with calcium- and diacylglycerolbinding motifs.
  21. (2005). JW: In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer research
  22. (1996). Lavin MF: The ICE family of cysteine proteases as effectors of cell death. Cell death and differentiation
  23. (2005). Linking tumor cell cytotoxicity to mechanism of drug action: an integrated analysis of gene expression, small-molecule screening and structural databases. Proteins
  24. (2001). Marette A: Amino acid and insulin signaling via the mTOR/ p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. The Journal of biological chemistry
  25. (2009). Nishigori C: 12-O-tetradecanoylphorbol-13-acetate inhibits melanoma growth by inactivation of STAT3 through protein kinase C-activated tyrosine phosphatase(s). The Journal of biological chemistry
  26. (2006). Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology
  27. (2009). PP: Combined inhibition of MEK and mammalian target of rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their proliferation. Cancer research
  28. (2003). PS: Analysis of the phosphatidylinositol 3’-kinase signaling pathway in glioblastoma patients in vivo. Cancer research
  29. (2003). Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells. Molecular cancer therapeutics
  30. (1996). Ras-GTP levels are elevated in human NF1 peripheral nerve tumors. Oncogene
  31. (2003). RD: BMPs signal alternately through a SMAD or FRAP-STAT pathway to regulate fate choice in CNS stem cells. The Journal of cell biology
  32. (2001). RO: Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer research
  33. Roles of PKC isoforms in the induction of apoptosis elicited by aberrant Ras.
  34. (2001). S: Iridals are a novel class of ligands for phorbol ester receptors with modest selectivity for the RasGRP receptor subfamily. Journal of medicinal chemistry
  35. (2001). Sauvaire Y: Cytotoxicity of iridals, triterpenoids from Iris, on human tumor cell lines A2780 and K562. Planta medica
  36. (2005). Signal transducer and activator of transcription 3 (STAT3) regulates human telomerase reverse transcriptase (hTERT) expression in human cancer and primary cells. Cancer research
  37. (1999). Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes & development
  38. (2007). Weiss WA: A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTENmutant glioma. Cancer research
  39. (2006). Weiss WA: A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer cell